Navidea Biopharmaceuticals has convinced Medicare to expand reimbursement for its Lymphoseek diagnostic aid, and the company locked down a manufacturing agreement with Siemens to cover its in-development Alzheimer's imaging tool.
Researchers at the Swiss Federal Institute of Technology in Lausanne and Asceneuron, a spinoff of Merck Serono, have discovered a key targeting mechanism to fight the buildup of amyloid plaque in the brain thought to cause early-onset Alzheimer's, and to do so with minimal side effects.
Takeda Pharmaceuticals and Zinfandel Pharmaceuticals say their new genetics-based Alzheimer's biomarker risk assignment algorithm generated promising results in early testing. A Phase III trial will advance the concept further, continuing a partnership between the companies formed more than two years ago.
Revalesio's investigational therapeutic RNS60 prevented memory loss and improved learning in mouse models, according to new data the company presented at the Alzheimer's Association International Conference Wednesday.
University of Pennsylvania researchers and others believe that earlier prediction of Alzheimer's disease may be possible by measuring amyloid plaque progression and patterning in the brain over time, rather than the end result.
Just two months after abruptly leaving Millennium as Takeda prepared to absorb its R&D work in its global research group and eliminate her position, Dunsire has been tapped as the new CEO at EnVivo Pharmaceuticals, a fast-growing drug developer in Watertown, MA focused on a late-stage CNS program for Alzheimer's and schizophrenia.
Eli Lilly has some allies for a brewing fight with Medicare. Alzheimer's groups are ready to back Amyvid, the company's imaging agent, in hopes that the Centers for Medicare and Medicaid Services will decide to pay for a diagnostic test after all.
Medicare has put up a big roadblock to Eli Lilly's Alzheimer's screening product Amyvid. The Centers for Medicare & Medicaid Services says it will only pay for the diagnostic agent if patients using it are in clinical trials, at least for now.
Amyloid beta plaque deposits in the brain serve as a clue to help diagnose Alzheimer's. But a related protein known as amylin also appears to build up in a major way. And researchers think it could eventually serve as another dementia or Alzheimer's biomarker.
Navidea is racing to get its beta-amyloid-detecting imaging agent on the market, kicking off enrollment in a Phase III trial for the Alzheimer's-related diagnostic.